RH Capital
VC Fund
RH Capital is a VC fund focused on Health Care and Women's. RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries RH Capital invests in
Stages RH Capital invests in
Countries RH Capital invests in
Investment Focus
Industry
- Health Care 12 (71%)
- Women's 5 (29%)
- Biotechnology 5 (29%)
- Medical Device 3 (18%)
- Health Diagnostics 3 (18%)
Stage
- Series A 10 (59%)
- Seed 5 (29%)
- Funding Round 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- United States 10 (59%)
- Canada 1 (6%)
- Israel 1 (6%)
- Switzerland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nadia Care
|
Cayaba Care is a maternal health company offering community-based clinical services via technology-enabled multidisciplinary care teams. | $12M / Venture - Series Unknown / Mar 16, 2026 | |
Eli
|
Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $12M / Series A / Jun 10, 2025 | |
Twentyeight Health
|
Twentyeight Health is a mission-driven women’s health platform, increasing access to healthcare services, starting with birth control.The company provides online doctor evaluations for birth control prescriptions, quick home deliveries, and secure messaging with doctors. Twentyeight Health also has sex ed content vetted by doctors so women canlearn about all their options. | $10M / Series A / Jan 07, 2025 | |
Novocuff
|
Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening. | $26M / Series A / Jul 17, 2024 | |
Seven Starling
|
Seven Starling is a digital clinic uniquely focused on treatment for perinatal mental health conditions like postpartum depression and anxiety. Through a combination of individualized therapy, peer support, and medication, its evidence-based care model is backed by research that shows that 90% of patients will feel better within 3 months. | $10.9M / Series A / Jul 16, 2024 | |
Ocon Healthcare
|
OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility. | $10M / Series A / Jun 24, 2024 | |
Raydiant Oximetry
|
Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy.This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections.Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California. | $7.5M / Series A / Jun 04, 2024 | |
Mae Health
|
Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes. | Seed / May 07, 2024 | |
Testmate Health
|
Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home. | $6M / Seed / May 02, 2024 | |
AOA
|
AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $17M / Oct 11, 2023 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does RH Capital invest in?
RH Capital invests primarily in Health Care, Women's and Biotechnology startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did RH Capital last invest?
The most recent investment recorded for RH Capital closed in Mar 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
